Breaking Update
Insightec Spins Out Lotus Neuro to Advance Brain Drug Delivery
Israeli-US focused ultrasound company Insightec spins out Lotus Neuro, a new biotech firm to speed brain-targeted drug delivery for neuro-oncology indications.
Jerusalem, 18 December, 2025 (TPS-IL) — Israeli-US focused ultrasound company Insightec announced the spin-out of Lotus Neuro, a new clinical-stage biotechnology firm aimed at advancing brain-targeted therapies using low-frequency focused ultrasound. Insightec, which is headquartered in Haifa and Miami, said the move is intended to accelerate drug delivery across the blood-brain barrier by pairing its device platform with advanced medicines. Lotus Neuro will initially focus on neuro-oncology indications, including glioblastoma.
The new company is funded by US-based Nexus NeuroTech Ventures and will be led by physician Arjun JJ Desai, formerly a senior executive at Insightec and at US healthcare group Johnson & Johnson.
